Dr Caroline Alvares
Timau a rolau for Caroline Alvares
Cyhoeddiad
2026
2025
2024
2023
2022
2020
Erthyglau
- Brady, O. P. et al. 2026. Random survival forest versus elastic-net regularized Cox regression for survival prediction in acute myeloid leukemia at distinct treatment time points: model performance comparison study. JMIR Bioinformatics and Biotechnology 7 e75678. (10.2196/75678)
- Dolton, G. et al., 2025. MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-α chain.. The Journal of Clinical Investigation 135 (1) e181895. (10.1172/JCI181895)
- Halilovic, M. et al., 2024. Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.. Leukemia 38 , pp.2561-2572. (10.1038/s41375-024-02405-5)
- Jonas, B. A. et al., 2023. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematological Oncology 41 (4), pp.743-752. (10.1002/hon.3159)
- Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186 (16), pp.3333-3349. E27. (10.1016/j.cell.2023.06.020)
- Chiriches, C. et al. 2022. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation. PLoS Genetics 18 (10) e1010463. (10.1371/journal.pgen.1010463)
- Zabkiewicz, J. et al. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191 (2), pp.231-242. (10.1111/bjh.16665)